HSB-888 / Canton Strategic Holdings - LARVOL DELTA

Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers (GlobeNewswire) - P=NA | N=NA | "'We proudly shared our progress at our R&D Day, notably our leading drug candidate ​​HSB-1216.'...HSB-1216 targets solid tumors as a ferroptosis-inducing agent and novel investigational treatment. The active in a clinical pilot study showed a 71% response rate and efficacy against devastating cancers, including triple-negative breast cancer and epithelial carcinomas...Hillstream is rapidly progressing towards an IND filing process and plans to initiate a clinical trial in solid tumor patients....HSB-888, Hillstream’s second product candidate is a Quatramer dual loaded with IMCD inducer coupled with our ultra-low dose, next generation anthracycline analogue for solid tumors."

Clinical data • IND • Breast Cancer • Melanoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • Uveal Melanoma